Clinical Trials on Hemolytic-Uremic Syndrome in Austria

Total 1332 results

Alexion Pharmaceuticals

Completed

An Open-Label, Multi-Center Clinical Trial of Eculizumab in Pediatric Patients With Atypical Hemolytic-Uremic Syndrome (aHUS)

Atypical Hemolytic-Uremic Syndrome

United Kingdom, Belgium, United States, Germany, Italy, France, Netherlands, Australia, Canada
Alexion Pharmaceuticals

Completed

Open Label Controlled Trial of Eculizumab in Adolescent Patients With Plasma Therapy-Resistant aHUS (aHUS)

Atypical Hemolytic Uremic Syndrome

France, United States, Austria, Germany, United Kingdom
Alexion
Syneos Health

Recruiting

Atypical Hemolytic-Uremic Syndrome (aHUS) Registry

Atypical Hemolytic-Uremic Syndrome

France, Germany, Israel, Italy, United Kingdom, Canada, United States, Australia, Belgium, Denmark, Korea, Republic of, Poland, Russian Federation, Spain, Taiwan
Alexion Pharmaceuticals

Terminated

aHUS Observational Long Term Follow-Up (LTFU)

Atypical Hemolytic Uremic Syndrome

France, Canada, United States, Belgium, Italy, United Kingdom, Netherlands, Australia, Austria, Germany, Sweden, Switzerland
Alexion Pharmaceuticals

Completed

Open Label Controlled Trial of Eculizumab in Adult Patients With Plasma Therapy-Resistant aHUS (aHUS)

Atypical Hemolytic Uremic Syndrome

France, United States, Austria, Germany, United Kingdom
Alexion Pharmaceuticals, Inc.

Completed

Study of ALXN1210 in Complement Inhibitor Treatment-Naïve Adult and Adolescent Participants With Atypical Hemolytic Uremic Syndrome (aHUS)

Atypical Hemolytic Uremic Syndrome (aHUS)

United States, France, Spain, Taiwan, United Kingdom, Australia, Belgium, Germany, Italy, Japan, Korea, Republic of, Russian Federation, Austria, Canada
Alexion

Completed

A Retrospective, Observational, Non-interventional Trial to Assess Eculizumab Treatment Effect in Patients With Atypical Hemolytic Uremic Syndrome (aHUS)

Atypical Hemolytic Uremic Syndrome (aHUS)

United States, France, Germany, Spain, Switzerland, Netherlands, Canada, Austria
Alexion Pharmaceuticals

Terminated

Evaluation of Potential Predictors of Disease Progression in Participants With Atypical Hemolytic Uremic Syndrome (aHUS) Including Genetics, Biomarkers, and Treatment (EVIDENCE)

Atypical Hemolytic Uremic Syndrome

United States, Australia, Germany, United Kingdom
Novartis Pharmaceuticals

Recruiting

Efficacy and Safety of Iptacopan (LNP023) in Adult Patients With Atypical Hemolytic Uremic Syndrome Naive to Complement Inhibitor Therapy (APPELHUS)

Atypical Hemolytic Uremic Syndrome

China, Korea, Republic of, Austria, Taiwan, Greece, Czechia, United States, Japan, Brazil, United Kingdom, India, Slovakia, Slovenia
Janssen Research & Development, LLC

Recruiting

A Study of Nipocalimab in Pregnancies at Risk for Severe Hemolytic Disease of the Fetus and Newborn (HDFN) (AZALEA)

Hemolytic Disease of the Fetus and Newborn

Israel, Brazil, Australia, United States, United Kingdom
Incyte Corporation

Completed

A Study of INCB050465 in Participants With Autoimmune Hemolytic Anemia

Autoimmune Hemolytic Anemia

United States, France, Italy, Austria
Rigel Pharmaceuticals

Enrolling by invitation

A Phase 3 Open Label Extension Study of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia

Warm Antibody Autoimmune Hemolytic Anemia

Spain, United States, Australia, Norway, Belarus, Germany, Netherlands, Belgium, Austria, Bulgaria, Czechia, France, Georgia, Italy, Russian Federation, Serbia, Ukraine, United Kingdom
Celgene

Completed

Study to Evaluate Additional Risk Minimisation Measures (aRMMs) for REBLOZYL Among Healthcare Professionals (HCPs)

Myelodysplastic Syndromes | Beta-thalassemia

Austria
Medical University of Graz

Active, not recruiting

Severe Immune Cytopenia Registry Www.Sic-reg.Org (sic-reg)

Primary Immunodeficiency | Immune Thrombocytopenia | Autoimmune Hemolytic Anemia | Evans Syndrome

Austria
Sanofi

Active, not recruiting

Efficacy, Safety and Pharmacokinetics of Rilzabrutinib in Patients With Warm Autoimmune Hemolytic Anemia (wAIHA)

Warm Autoimmune Hemolytic Anemia (wAIHA)

United States, Austria, China, Denmark, Germany, Hungary, Italy, Spain, United Kingdom
Rigel Pharmaceuticals

Completed

A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of Fostamatinib Disodium in the Treatment of wAIHA

Warm Antibody Autoimmune Hemolytic Anemia

United States, Spain, Canada, Australia, Norway, France, Belarus, Germany, Netherlands, Belgium, United Kingdom, Austria, Czechia, Georgia, Italy, Russian Federation, Serbia, Ukraine, Romania, Denmark, Hungary, Bulgaria
Incyte Corporation

Active, not recruiting

Study of the Efficacy and Safety of Parsaclisib in Participants With Primary Warm Autoimmune Hemolytic Anemia (PATHWAY)

Warm Autoimmune Hemolytic Anemia (wAIHA)

Spain, United States, Austria, Belgium, Canada, France, Germany, Israel, Italy, Japan, Netherlands, Poland, United Kingdom
Novartis Pharmaceuticals

Recruiting

A Study of Efficacy and Safety of Ianalumab in Previously Treated Patients With Warm Autoimmune Hemolytic Anemia (VAYHIA)

Warm Autoimmune Hemolytic Anemia (wAIHA)

China, Japan, Spain, Singapore, France, Germany, Taiwan, United States, Italy, India, Malaysia, Argentina, Hungary, Israel, Australia, Thailand, United Kingdom, Romania
Bioverativ, a Sanofi company
Assign Data Management and Biostatistics GmbH; Quest Diagnostics-Nichols Insitute and other collaborators

Completed

Safety, Tolerability and Activity of BIVV009 in Healthy Volunteers and Patients With Complement Mediated Disorders (BIVV009-01)

End-stage Renal Disease (ESRD) | Cold Agglutinin Disease (CAD) | Bullous Pemphigoid (BP) | Warm Autoimmune Hemolytic Anemia (WAIHA)

Austria
Janssen Research & Development, LLC

Active, not recruiting

A Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of M281 Administered to Pregnant Women at High Risk for Early Onset Severe Hemolytic Disease of the Fetus and Newborn (HDFN)

Hemolytic Disease of the Fetus and Newborn

United States, Canada, Netherlands, Belgium, Germany, Spain, Sweden, United Kingdom, Australia
Kezar Life Sciences, Inc.

Withdrawn

A Phase 2 Study to Evaluate the Safety and Efficacy of KZR-616 in Patients With AIHA and ITP (MARINA)

Immune Thrombocytopenia | Autoimmune Hemolytic Anemia

Poland, United States, Australia, Italy, Russian Federation
Alpine Immune Sciences, Inc.

Recruiting

An Open-label Study of Povetacicept in Subjects With Autoimmune Cytopenias (RUBY-4)

Immune Thrombocytopenia | Idiopathic Thrombocytopenic Purpura | Cold Agglutinin Disease | Warm Autoimmune Hemolytic Anemia

United States, Canada, Australia, Turkey, United Kingdom
Medical University of Vienna
Croma-Pharma GmbH

Completed

Assessment of Safety and Tolerability of Chitosan-N-acetylcysteine Eye Drops in Subjects While Wearing Contact Lenses and Before Insertion of Contact Lenses

Dry Eye Syndrome

Austria
Gerhard Garhofer
Croma-Pharma GmbH

Completed

Evaluation of the Corneal Residence Time of Chitosan-N-acetylcysteine Eye Drops in Patients With Dry Eye Syndrome After Single and Multiple Instillation

Dry Eye Syndrome

Austria
Medical University of Vienna

Completed

Difference in the Frequency of Use of Lachrymal Substitutes in Patients With Moderate to Severe Dry Eye Syndrome

Dry Eye Syndromes

Austria
Medical University of Vienna

Completed

Added Benefits of Lachrymal Substitute Gel During the Night in Patients With Moderate to Severe Dry Eye Syndrome

Dry Eye Syndromes

Austria
Medical University of Vienna

Completed

Influence of Lachrymal Substitutes on Tear Film Thickness in Patients With Moderate Dry Eye Syndrome

Dry Eye Syndrome

Austria
Medical University of Vienna

Terminated

Near Infrared Spectroscopy in Patients Undergoing Robotic Assisted Laparoscopic Surgery in the Trendelenburg Position

Nontraumatic Compartment Syndrome of Leg

Austria
Medical University of Vienna

Completed

Effect of Single Instillation of Three Different Topical Lubricants on Tear Film Thickness in Patients With Dry Eye Syndrome

Dry Eye Syndromes

Austria
Medical University of Vienna

Completed

Influence of Three Different Formulations of Lachrymal Substitutes on Tear Film Thickness and Other Signs and Symptoms in Patients With Moderate to Severe Dry Eye Syndrome

Dry Eye Syndromes

Austria
Medical University of Vienna

Completed

Influence of Lachrymal Substitute Gels on Tear Film Thickness in Patients With Moderate to Severe Dry Eye Syndrome

Dry Eye Syndromes

Austria
Medical University of Vienna

Completed

Correlation of Different Signs for Assessment of Dry Eye Syndrome

Dry Eye Syndrome

Austria
Medical University of Vienna

Completed

Reproducibility of Tearfilm Osmolarity Measurements Using TearLab® in Patients With Dry Eye Syndrome and Healthy Subjects

Dry Eye Syndrome

Austria
Medical University of Vienna

Completed

Effect of Olixia Pure® Eye Drops on Tear Film Thickness in Healthy Subjects

Healthy | Dry Eye Syndrome

Austria
Medical University of Vienna

Withdrawn

Treatment of Dry Eye With Supplements

Dry Eye Syndromes

Austria
Michael Pfeilstöcker
Celgene Corporation

Completed

Analysis of Risk in MDS Over Time - Comparison of Treated vs Untreated Patients

Myelodysplastic Syndromes

Austria
Andrew Steer
National Health and Medical Research Council, Australia; Queen Fabiola Children... and other collaborators

Completed

Controlled Human Infection for Vaccination Against Streptococcus Pyogenes (CHIVAS)

Bacterial Infections | Gram-Positive Bacterial Infections | Strep Throat | Streptococcus Pharyngitis | Streptococcus Pyogenes Pharyngitis | Streptococcus Pyogenes Infection | Group A Streptococcus: B Hemolytic Pharyngitis | Group A Streptococcal Infection

Australia
Medical University of Vienna

Recruiting

Effect of Topical Azithromycin on Tear Film Thickness in Patients With Meibomian Gland Dysfunction

Dry Eye Syndromes | Meibomian Gland Dysfunction

Austria
Medical University of Vienna

Completed

Local Tolerability of Chitosan-N-acetylcysteine Eye Drops in Healthy Young Volunteers

Dry Eye Syndromes

Austria
Ionis Pharmaceuticals, Inc.

Completed

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISIS 702843 Administered Subcutaneously to Healthy Volunteers

Thalassemia

Australia
Medical University of Vienna

Unknown

Surgical Treatment Of Complex Regional Pain Syndrome Type II (CRPS II)

CRPS Type II

Austria
Medical University of Vienna

Completed

Safety and Tolerability of Chitosan-N-acetylcysteine Eye Drops in Healthy Young Volunteers

Dry Eye Syndromes

Austria
Hospital Hietzing

Completed

Effect of Ciclosporin Eyedrops on Sjögren Syndrome

Dry Eye Syndromes

Austria
BioCryst Pharmaceuticals

Completed

First-in-Human Study of BCX9930 in Healthy Volunteers and Patients With PNH

Paroxysmal Nocturnal Hemoglobinuria

United Kingdom, Austria, South Africa
Medical University Innsbruck
University Hospital, Bonn; Universitätsklinikum Leipzig

Recruiting

Sterile Inflammation and Molecular Aberrations in MDS (InflamGen)

Myelodysplastic Syndromes

Austria
Celgene

Recruiting

A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials

Beta-thalassemia | Myelodysplastic Syndromes (MDS) | Myeloproliferative Neoplasm(MPN)-Associated Myelofibrosis

United States, Japan, Israel, United Kingdom, Turkey, Greece, France, Australia, Belgium, Bulgaria, Canada, Germany, Italy, Malaysia, Spain, Sweden, Taiwan, Thailand, Tunisia, China, Lebanon, Netherlands
Medical University of Vienna

Unknown

Effectiveness of fESWT in the Treatment of CTS

Carpal Tunnel Syndrome

Austria
Medical University of Vienna

Completed

Bridging Intestinal Failure With Teduglutide - a Case Report

Short Bowel Syndrome

Austria
Dompé Farmaceutici S.p.A
Cross Research S.A.

Completed

Safety and Efficacy of rhNGF Eye Drops at Different Doses in Patients With Dry Eye

Dry Eye Syndrome

Austria
The University of Queensland
Royal Brisbane and Women's Hospital

Unknown

Exercise in Critically Ill Patients With Sepsis

Sepsis Syndromes

Australia

Clinical Trials on Hemolytic-Uremic Syndrome in Austria

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Papua New Guinea

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations